Neurological and histological consequences induced by in vivo cerebral oxidative stress: Evidence for beneficial effects of SRT1720, a sirtuin 1 activator, and sirtuin 1-mediated neuroprotective effects of poly(ADP-ribose) polymerase inhibition

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Gueguen, Cindy ^a   Palmier, Bruno ^a   Plotkine, Michel ^a   Marchand Leroux, Catherine ^a   Bessson, Valérie C ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; A 0788; EX 527; MALONIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; S 1129; SIRTUIN 1; SRT 1720; UNCLASSIFIED DRUG; 3-AMINOBENZAMIDE; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; BENZAMIDE DERIVATIVE; CARBAZOLE DERIVATIVE; FUSED HETEROCYCLIC RINGS; MALONIC ACID DERIVATIVE; N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; IMMUNOBLOTTING; METABOLISM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; BLOTTING, WESTERN; BRAIN; CARBAZOLES; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; IMMUNOBLOTTING; MALE; MALONATES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; SIRTUIN 1; STATISTICS, NONPARAMETRIC;

EID: 84896138015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087367     Document Type: Article

References (60)

1. Margaill I, Plotkine M, Lerouet D (2005) Antioxidant strategies in the treatment of stroke. Free Radic Biol Med 39: 429-443. doi:10.1016/j. freeradbiomed.2005.05.003. (Pubitemid 41021642)
2. Besson VC (2009) Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation. Br J Pharmacol 157: 695-704. doi:10.1111/j.1476-5381.2009.00229.x.
3. Hall ED, Vaishnav RA, Mustafa AG (2010) Antioxidant therapies for traumatic brain injury. Neurotherapeutics 7: 51-61. doi:10.1016/j.nurt.2009.10. 021.
4. Abeti R, Abramov AY, Duchen MR (2011) Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134 (Pt 6): 1658-1672. doi: 10.1093/brain/awr104.
5. Strosznajder RP, Czubowicz K, Jesko H, Strosznajder JB (2010) Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology. Mol Neurobiol 41: 187-196. doi:10.1007/s12035-010-8124-6.
6. Komjáti K, Besson VC, Szabó C (2005) Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma. Curr Drug Targets CNS Neurol Disord 4: 179-194.
7. Schraufstatter IU, Hyslop PA, Hinshaw DB, Spragg RG, Sklar LA, et al. (1986) Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A 83: 4908-4912. (Pubitemid 16075508)
8. Besson VC, Margaill I, Plotkine M, Marchand-Verrecchia C (2003) Deleterious activation of poly(ADP-ribose)polymerase-1 in brain after in vivo oxidative stress. Free Radic Res 37: 1201-1208. (Pubitemid 37322198)
9. Bai P, Cantó C, Oudart H, Brunyánszki A, Cen Y, et al. (2011) PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 13: 461-468. doi:10.1016/j.cmet.2011.03.004.
10. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13. doi:10.1042/BJ20070140. (Pubitemid 46788079)
11. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148. (Pubitemid 33035941)
12. Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305: 1010-1013. doi:10.1126/science.1098014. (Pubitemid 39071777)
13. Pillai JB, Isbatan A, Imai S, Gupta MP (2005) Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 280: 43121-43130. doi:10.1074/jbc.M506162200. (Pubitemid 43049278)
14. Furukawa A, Tada-Oikawa S, Kawanishi S, Oikawa S (2007) H2O2 accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD+ depletion. Cell Physiol Biochem 20: 45-54. doi:10.1159/000104152. (Pubitemid 46956811)
15. Caito S, Hwang J-W, Chung S, Yao H, Sundar IK, et al. (2010) PARP-1 inhibition does not restore oxidant-mediated reduction in SIRT1 activity. Biochem Biophys Res Commun 392: 264-270. doi:10.1016/j.bbrc.2009.12.161.
16. Ying W, Alano CC, Garnier P, Swanson RA (2005) NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res 79: 216-223. doi:10.1002/jnr.20289. (Pubitemid 40116438)
17. Paucard A, Besson VC, Plotkine M, Margaill I (2005) Time course of oxidative stress, lesion and edema after intrastriatal injection of malonate in rat: effect of alpha-phenyl-N-tert-butylnitrone. Fundam Clin Pharmacol 19: 57-64. doi:10.1111/j.1472-8206.2004.00297.x. (Pubitemid 40204347)
18. Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, et al. (1995) Involvement of free radicals in excitotoxicity in vivo. J Neurochem 64: 2239-2247.
19. Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press.
20. Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates. Academic Press. 451 p.
21. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA (1997) Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab 17: 1143-1151. doi:10.1097/00004647-199711000-00002. (Pubitemid 27514738)
22. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716. doi:10.1038/nature06261. (Pubitemid 350207685)
23. Velásquez DA, Martínez G, Romero A, Vázquez MJ, Boit KD, et al. (2011) The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 60: 1177-1185. doi:10.2337/db10-0802.
24. Besson VC, Croci N, Boulu RG, Plotkine M, Marchand-Verrecchia C (2003) Deleterious poly(ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat. Brain Res 989: 58-66. (Pubitemid 37281402)
25. Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C (2008) Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J Pharmacol Exp Ther 326: 966-974. doi:10.1124/jpet.108.140368.
26. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, et al. (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472-476. (Pubitemid 16085691)
27. Golanov EV, Reis DJ (1995) Contribution of cerebral edema to the neuronal salvage elicited by stimulation of cerebellar fastigial nucleus after occlusion of the middle cerebral artery in rat. J Cereb Blood Flow Metab 15: 172-174. doi:10.1038/jcbfm.1995.19.
28. Bernofsky C, Swan M (1973) An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem 53: 452-458.
29. Shah GM, Poirier D, Duchaine C, Brochu G, Desnoyers S, et al. (1995) Methods for biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo. Anal Biochem 227: 1-13. doi:10.1006/abio.1995.1245.
30. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y (2007) Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem 282: 6823-6832. doi:10.1074/jbc.M609554200. (Pubitemid 47100909)
31. Shinmura K, Tamaki K, Bolli R (2008) Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1. Am J Physiol Heart Circ Physiol 295: H2348-2355. doi:10.1152/ajpheart.00602.2008.
32. Cosi C, Cavalieri E, Carcereri de Prati A, Marien M, Suzuki H (2000) Effects of kainic acid lesioning on poly(ADP-ribose) polymerase (PARP) activity in the rat striatum in vivo. Amino Acids 19: 229-237.
33. Ying W (2008) NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10: 179-206. doi:10.1089/ars.2007.1672.
34. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, et al. (2010) NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30: 2967-2978. doi:10.1523/JNEUROSCI.5552-09.2010.
35. Clark RSB, Vagni VA, Nathaniel PD, Jenkins LW, Dixon CE, et al. (2007) Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J Neurotrauma 24: 1399-1405. doi:10.1089/neu.2007.0305. (Pubitemid 47340100)
36. Yang J, Klaidman LK, Nalbandian A, Oliver J, Chang ML, et al. (2002) The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats. Neurosci Lett 333: 91-94. (Pubitemid 35284892)
37. Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP (2009) Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromolecular Med 11: 28-42. doi:10.1007/s12017-009-8058-1.
38. Wu A, Ying Z, Gomez-Pinilla F (2007) Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma 24: 1587-1595. doi:10.1089/neu.2007.0313. (Pubitemid 350035841)
39. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr, et al. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68: 48-58. doi:10.1097/NEN.0b013e3181922348.
40. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, et al. (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8: 347-358. doi:10.1016/j.cmet.2008.08.017.
41. Yamazaki Y, Usui I, Kanatani Y, Matsuya Y, Tsuneyama K, et al. (2009) Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab 297: E1179-1186. doi:10.1152/ajpendo.90997.2008.
42. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, et al. (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29: 1363-1374. doi:10.1128/MCB.00705-08.
43. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, et al. (2010) SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298: E419-428. doi:10.1152/ajpendo. 00417.2009.
44. Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, et al. (2011) SRT1720 improves survival and healthspan of obese mice. Sci Rep 1: 70. doi:10.1038/srep00070.
45. Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, et al. (2012) Pharmacokinetics and Tolerability of SRT2104, a First-In-Class Small Molecule Activator of SIRT1, after Single and Repeated Oral Administration in Man. Bri tish journal of clinical pharmacology. doi :10.1111/j.1365-2125.2012.04340.x.
46. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196. doi:10.1038/nature01960. (Pubitemid 37150899)
47. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, et al. (2009) Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 159: 993-1002. doi:10.1016/j.neuroscience.2009.01.017.
48. Gupta YK, Chaudhary G, Sinha K, Srivastava AK (2001) Protective effect of resveratrol against intracortical FeCl3-induced model of posttraumatic seizures in rats. Methods Find Exp Clin Pharmacol 23: 241-244. (Pubitemid 33009601)
49. Sinha K, Chaudhary G, Gupta YK (2002) Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 71: 655-665. (Pubitemid 34628827)
50. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, et al. (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-447. (Pubitemid 35441199)
51. Zhang F, Liu J, Shi J-S (2010) Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 636: 1-7. doi:10.1016/j.ejphar.2010.03.043.
52. Kolthur-Seetharam U, Dantzer F, McBurney MW, De Murcia G, Sassone-Corsi P (2006) Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 5: 873-877. (Pubitemid 44145583)
53. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, et al. (2009) SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009 29(15): 4116-29. doi: 10.1128/MCB.00121-09.
54. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, et al. (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28-38. doi:10.1128/MCB.26.1.28-38.2006.
55. Ba X, Garg NJ (2011) Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol 178: 946-955. doi:10.1016/j.ajpath.2010.12.004.
56. Oliver FJ, Ménissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, et al. (1999) Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 18: 4446-4454. doi:10.1093/emboj/18.16.4446. (Pubitemid 29391254)
57. Xie J, Zhang X, Zhang L (2013) Negative regulation of inflammation by SIRT1. Pharmacological Research 67: 60-67. doi:10.1016/j.phrs.2012.10.010.
58. Yang H, Zhang W, Pan H, Feldser HG, Lainez E, et al. (2012) SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS ONE 7: e46364. doi:10.1371/journal.pone.0046364.
59. Kauppinen TM, Gan L, Swanson RA (2013) Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-κB transcriptional activity by preventing p65 de-acetylation. Biochim Biophys Acta 1833: 1985-1991. doi:10.1016/j.bbamcr.2013.04.005.
60. Ichikawa T, Hayashi R, Suzuki K, Imanishi S, Kambara K, et al. (2013) Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology 18: 332-339. doi:10.1111/j.1440-1843.2012. 02284.x.